In-silico ADMET and molecular docking evaluation of an active cyclopeptide from a Saharan Streptomyces strain with anticancer, anti-HIV, and anti- SARS-CoV-2 activities
DOI:
https://doi.org/10.34119/bjhrv7n9-448Keywords:
molecular docking, ADMET properties, Cyclo(L-pro-L-tyr), Anti-SARS-CoV-2 and anti-HIV activities, anti-breast câncerAbstract
The emergence of new SARS-CoV-2 variants, HIV drug resistance, and the persistent burden of breast cancer have created an urgent need to identify new antiviral and anticancer drug candidates. In this investigation, we employed in-silico methods to evaluate the pharmacokinetic proprieties and toxicity, and the inhibitory potential of a cyclic peptide compound produced by a novel Streptomyces strain using target enzymes. In silico analysis of the ADMET profile indicates that the cyclic peptide cyclo(L-pro-L-tyr) has favorable physicochemical properties, good lipophilicity and water solubility, generally favorable pharmacokinetic characteristics, and low toxicity for the cyclic peptide. In addition, the docking studies of the compound showed strong binding affinities with HIV-1 integrase at -7.4 kcal/mol, HIV-1 reverse transcriptase at -8.1 kcal/mol, COVID-19 main protease at -8.5 kcal/mol, and SARS-CoV-2 spike glycoprotein at -7.7 kcal/mol compared to references inhibitors. Furthermore, it has a good binding affinity with estrogen receptor alpha associated with breast cancer at -6.8 kcal/mol compared to reference inhibitors. Therefore, the findings demonstrate the potential of cyclo(L-pro-L-tyr) as a novel bioactive compound with antiviral and anticancer properties. This means that it needs to be tested in more experiments and further developed as a lead compound for treating SARS-CoV-2 infections, HIV/AIDS, and breast cancer.
References
ANAND, K., ZIEBUHR, J., WADHWANI, P., MESTERS, J.R., HILGENFELD, R. Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs. Science, v.300, n. 5626, p 1763–7. 2003. https://doi.org/10.1126/science.1085658
ARNOLD, M., MORGAN, E., RUMGAY, H., MAFRA, A., SINGH, D., LAVERSANNE, M., VIGNAT, J., GRALOW, J.R., CARDOSO, F., SIESLING, S., SOERJOMATARAM, I.. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast, v 59. n.106, p106–117. 2022. https://doi.org/10.1016/j.breast.2022.08.010
BABY, K., MAITY, S., MEHTA, C.H., SURESH, A., NAYAK, U.Y., NAYAK, Y. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Arch Med Res, v. 52, N.1, p 38–47. 2021. https://doi.org/10.1016/j.arcmed.2020.09.013
CHEN, G., SEUKEP, A.J., GUO, M. Recent Advances in Molecular Docking for the Research and Discovery of Potential Marine Drugs. Mar Drugs, v.18, n.11, p 545. 2020. https://doi.org/10.3390/md18110545
Chen, Xiaoxin, Huang, X., Ma, Q., Kuzmič, P., Zhou, B., et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol, v.9, p 1075–1088. 2024. https://doi.org/10.1038/s41564-024-01618-9
Craik, D.J., Fairlie, D.P., Liras, S., Price, D., 2013. The Future of Peptide-based Drugs. Chem Biol Drug Des,v. 81, n.1, p 136–147. 2012. https://doi.org/10.1111/cbdd.12055
Daina, A., Michielin, O., Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep, v.7, n. 7, p 42717. 2017.https://doi.org/10.1038/srep42717
Demoliou, C., Papaneophytou, C., Nicolaidou, V. SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune Response at the Cellular and Molecular Level. Int J Med Sci,
v. 19, n.12, p 1787-1795. 2022. https://doi.org/10.7150/ijms.73134
DRICHE, E., BADJI, B., MATHIEU, F., ZITOUNI, A. In-vitro antibacterial and antibiofilm activities and in-silico analysis of a potent cyclic peptide from a novel Streptomyces sp . strain RG-5 against antibiotic-resistant and biofilm-forming pathogenic bacteria. Archives of Microbiology, v. 206, n. 450, p 1–16, 2024. https://doi.org/10.1007/s00203-024-04174-2
DRICHE, E.H., BADJI, B., BIJANI, C., BELGHIT, S., PONT, F., MATHIEU, F., ZITOUNI. A. Antibacterial and antibiofilm properties of two cyclic dipeptides produced by a new desert Streptomyces sp. HG-17 strain against multidrug-resistant pathogenic bacteria. Int Microbiol, 2024. https://doi.org/10.1007/s10123-024-00533-7
FERREIRA, L.L.G., ANDRICOPULO, A.D. ADMET modeling approaches in drug discovery. Drug Discov Today, 2019. https://doi.org/10.1016/j.drudis.2019.03.015
FISCHER, W., GIORGI, E.E., CHAKRABORTY, S., NGUYEN, K., BHATTACHARYA, T., et al. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host Microbe 2021. https://doi.org/10.1016/j.chom.2021.05.012
GRAU-BEJAR, J.F., GARCIA-DURAN, C., GARCIA-ILLESCAS, D., MIRALLAS, O., OAKNIN, A. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol, 2023. https://doi.org/10.1177/17588359231163836
KHELFAOUI, H., HARKATI, D., SALEH, B.A. Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. J Biomol Struct Dyn, v. 38, n. 18, p 7246–7262. 2021. https://doi.org/10.1080/07391102.2020.1803967
KOLA, I., LANDIS, J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov v.3, n.3, p 711–716. 2004. https://doi.org/10.1038/nrd1470
LIPINSKI, C.A., LOMBARDO, F., DOMINY, B.W., FEENEY, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 2012. https://doi.org/10.1016/j.addr.2012.09.019
LIPINSKI, C.A., LOMBARDO, F., DOMINY, B.W., FEENEY, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 2001. https://doi.org/10.1016/S0169-409X(00)00129-0
OBACH, R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition, v. 27, n. 11, p 1350–9.1999
PESSINO, G., SCOTTI, C., MAGGI, M. Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets. Cancer, v. 6, n. 5, p 901. 2024. https://doi.org/10.3390/cancers16050901
RAMADHANI, D., MAHARANI, R., GAZZALI, A.M., MUCHTARIDI, M. Cyclic Peptides for the Treatment of Cancers: A Review. Molecules, v. 27, n. 14, p 4428. 2022. https://doi.org/10.3390/molecules27144428
RIBEIRO, R., PINTO, E., FERNANDES, C., SOUSA, E. Marine Cyclic Peptides: Antimicrobial Activity and Synthetic Strategies. Mar Drugs, v. 20, n. 6, p 397. 2022, https://doi.org/10.3390/md20060397
THUERAUF, N., FROMM, M.F. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci, v. 256, p 281–286. 2006. https://doi.org/10.1007/s00406-006-0662-6
VILLOUTREIX, B.O., TABOUREAU, O. Computational investigations of hERG channel blockers: New insights and current predictive models. Adv Drug Deliv Rev, v. 86, n. 23, p 72–82. 2015. https://doi.org/10.1016/j.addr.2015.03.003
